

## **Intersect ENT Announces Publication of PROGRESS Study of Steroid Releasing Implant in Patients With Frontal Sinus Disease**

*Results Demonstrate Clinical Benefits of PROPEL mini in Difficult-to-Treat Patient Population*

MENLO PARK, Calif.—July 11, 2016—Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced publication of results of the PROPEL® mini cohort of the PROGRESS study in *The Laryngoscope*. PROGRESS was a prospective, randomized, blinded, multi-center trial to assess the safety and efficacy of the PROPEL® mini steroid releasing sinus stent when used following frontal sinus surgery with standard postoperative care.

As previously reported, the study met its primary efficacy endpoint, demonstrating a statistically significant 38% relative reduction in the need for post-operative interventions ( $p=0.007$ ) at 30 days compared to surgery alone with standard post-operative care. Post-operative interventions included the need for additional surgical procedures and/or need for oral steroids. Clinical investigators also reported a 54% relative reduction in restenosis, a 56% relative reduction in the need for oral steroids, and a 75% relative reduction in the need for surgical interventions on sides treated with PROPEL mini compared to surgery alone at 30 days. The device placement success rate was 100% and there were no device-related adverse events.

In March 2016 Intersect ENT received approval for an expanded indication from the U.S. Food and Drug Administration (FDA) for placement of PROPEL mini in the frontal sinuses, which are located behind the eyebrows.

“The results from the PROGRESS study are important because they demonstrate that PROPEL mini improves the outcomes of frontal sinus surgery when added to standard postoperative care in chronic sinusitis patients with frontal sinus disease undergoing sinus surgery,” said Randall Ow, M.D. of Sacramento Ear, Nose, and Throat, a lead enroller in the study. “The recent expanded indication for PROPEL mini was much anticipated because the frontal sinus is more difficult to operate on and to manage post-operatively, compared to the other sinuses.”

“The positive outcomes from PROGRESS add to the growing clinical evidence demonstrating the benefits of steroid releasing implants,” said Lisa Earnhardt, president and CEO, Intersect ENT. “Frontal sinusitis affects as many as one in four patients undergoing surgery for chronic sinusitis. We are excited that this patient population now has access to treatment with PROPEL mini.”

### **ABOUT PROPEL and PROPEL mini**

Intersect ENT’s PROPEL and PROPEL mini are the first and only steroid releasing sinus implants approved by the FDA to maintain the open passages created in surgery. The bioabsorbable products release mometasone furoate, an advanced steroid with anti-inflammatory properties, over time directly into the sinus lining, then fully dissolve. PROPEL’s effectiveness is supported by the highest level of clinical evidence, Level 1a, which demonstrates that PROPEL reduces inflammation and scarring after surgery, thereby lessening the need for post-operative surgical interventions and use of oral

steroids. Both PROPEL and PROPEL mini are indicated for use following ethmoid sinus surgery. Additionally, PROPEL mini is indicated for use following frontal sinus surgery.

More than 100,000 U.S. patients have been treated with PROPEL and PROPEL mini.

## **ABOUT INTERSECT ENT**

Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL and PROPEL mini, which have been clinically proven to improve surgical outcomes for chronic sinusitis patients undergoing sinus surgery. In addition, Intersect ENT is developing a pipeline of steroid releasing implants designed to provide ENT physicians with options to treat patients across the continuum of care for chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition that can lead to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.

For additional information on the company or the products including risks and benefits please visit [www.intersectENT.com](http://www.intersectENT.com).

INTERSECT ENT<sup>®</sup> and PROPEL<sup>®</sup> are registered trademarks of Intersect ENT, Inc.

## **Forward-Looking Statements**

The statements in this press release regarding Intersect ENT's continued growth and the development of future products are "forward-looking" statements. These forward-looking statements are based on Intersect ENT's current expectations and inherently involve significant risks and uncertainties. These statements include those related to the potential surgical outcomes for patients with chronic sinusitis and the potential benefits of the use of the company's products. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, the performance of PROPEL and PROPEL mini, and the development of competitive products. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Intersect ENT's filings on Form 10-K, Form 10-Q and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ([www.sec.gov](http://www.sec.gov)). Intersect ENT does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

XENT-G

**Media Contact:** Nicole Osmer  
650.454.0504  
[nicole@nicoleosmer.com](mailto:nicole@nicoleosmer.com)

**Investor Contact:** Jeri Hilleman  
650.641.2105

ir@intersectent.com